Dose and cost comparison of erythropoietic agents in the inpatient hospital setting

American Journal of Health-System Pharmacy

Volumn 64, Issue 18, 2007, Pages 1943-1949

  Vekeman, Francis ^a   McKenzie, R Scott ^b   Lefebvre, Patrick ^a   Watson, Sue H ^c   Mody, Samir H ^d   Piech, Catherine Tak ^e   Duh, Mei Sheng ^f  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^b Ortho Biotech Clinical Affairs LLC (OBCA)   (United States)

^c OBCA   (United States)

^d OBCA   (United States)

^e OBCA   (United States)

^f ANALYSIS GROUP   (United States)

Author keywords

Costs; Darbepoetin alfa; Dosage; Drug comparisons; Epoetin alfa; Hematopoietic agents; Kidney diseases; Neoplasms

Indexed keywords

ERYTHROPOIETIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; DRUG DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DRUG COST; DRUG DOSE COMPARISON; FEMALE; HEALTH CARE COST; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; ANEMIA; COHORT ANALYSIS; COMPARATIVE STUDY; ECONOMICS; HOSPITAL PHARMACY; KIDNEY DISEASE; MIDDLE AGED; NEOPLASM; RETROSPECTIVE STUDY;

ADULT; AGED; ANEMIA; COHORT STUDIES; EPOETIN ALFA; ERYTHROPOIETIN; FEMALE; HEALTH CARE COSTS; HUMANS; INPATIENTS; KIDNEY DISEASES; MALE; MIDDLE AGED; NEOPLASMS; PHARMACY SERVICE, HOSPITAL; RETROSPECTIVE STUDIES;

EID: 34548744109     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060585     Document Type: Article

References (32)

1. Witzig TE, Silberstein PT, Loprinzi CL et al. Phase III, randomized, double-blind study of epoetin alfa versus placebo in anemic patients with cancer undergoing chemotherapy. J Clin Oncol. 2004; 22:1-12.
2. Provenzano R, Garcia-Mayol L, Suchinda P et al. Once-weekly epoetin alfa for treating the anemia of chronic kidney disease. Clin Nephrol. 2004; 61:392-405.
3. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39(suppl 1):S1-266.
4. Procrit (epoetin alfa) package insert. Thousand Oaks, CA: Amgen. www.procrit.com/common/prescribing_information/PROCRIT/PDF/ProcritBooklet.pdf (accessed 2006 Aug 3).
5. Aransep (darbepoetin alfa) package insert. Thousand Oaks, CA: Amgen. www.aranesp.com/pdf/aranesp_PI.pdf (accessed 2006 Aug 3).
6. Gabrilove JL, Cleelan CS, Livingston RB et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvement in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol. 2001; 19:2875-82.
7. Nissenson AR, Swan SK, Lindberg JS et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis. 2002; 40:110-8.
8. Schwartzberg L, Shiffman R, Tomita D et al. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Clin Ther. 2003; 23:2781-96.
9. Chang J, Couture F, Young S et al. Once weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol. 2004; 23:2597-605.
10. Rosberg JH, Ben-Hamadi R, Cremieux PY et al. Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anaemia: a meta-analysis. Clin Drug Invest. 2005; 25:33-48.
11. Waltzman R, Croot C, Justice GR et al. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 μg every 2 weeks) in anemic patients with cancer receiving chemotherapy. Oncologist. 2005; 10:642-50.
12. Ben-Hamadi R, Duh MS, Aggarwal J et al. The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia. Curr Med Res Opin. 2005; 21:1677-82.
13. Papatheofanis FJ, McKenzie RS, Mody SH et al. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia. Curr Med Res Opin. 2006; 22:837-42.
14. Anderson ER, Gibson G. Consideration in darbepoetin alfa cost and reimbursement: a model for pharmacy managers. Pharmacotherapy. 2003; 23:119S-24S.
15. Morreale A, Plowman B, DeLattre M et al. Clinical and economic comparison of epoetin alfa and darbepoetin alfa. Cur Med Res Opin. 2004; 20:381-95.
16. Hoffman JM, Shah ND, Vermeulen LC et al. Projecting future drug expenditures - 2005. Am J Health-Syst Pharm. 2005; 62:149-67.
17. Kruep EJ, Basskin LE. Cost-minimization analysis of darbepoetin alfa versus epoetin alfa in the hospital setting. Am J Health-Syst Pharm. 2005; 62:2597-603.
18. Averill RF, Goldfield G, Hughes JS et al. All patient refined diagnosis-related groups (APR-DRGs) version 20.0: methodology overview. Wallingford, CT: 3M Health Information Systems.
19. Red Book Ready Price software. List price for Procrit and Aranesp from September 2006. Greenwood Village, CO: Thomson PDR; 2006.
20. Centers for Medicare and Medicaid Services. ASP drug pricing files and NDC-HCPCS crosswalks. www.cms.hhs.gov/McrPartBDrugAvgSalesPrice/02_aspfiles. asp#TopOfPa (accessed 2006 Sep 22).
21. Vadhan-Raj S, Mirtsching B, Cham V et al. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks. J Support Oncol. 2003; 1:131-8.
22. Toto RD, Pichette V, Navarro J et al. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration. Am J Nephrol. 2004; 24:453-60.
23. Gosselin A, Lefebvre P, Duh MS et al. Dosing patterns and transfusion use in cancer patients treated with erythropoietic agents: results of an observational study of over 8,000 patients. Blood. 2005; 106:872. Abstract 3118.
24. Harley C, Muser E, Nelson M et al. Resource use and anemia-related treatment costs among cancer patients treated with epoetin alfa or darbepoetin alfa. J Manag Care Pharm. 2005; 11:616. Abstract.
25. Barron J, Mody S, Boudreaux M et al. Dosing distribution patterns and associated costs of erythropoietic agents in patients with pre-dialysis chronic kidney disease from three large managed care organizations. J Am Soc Nephrol. 2005; 16:967. Abstract F-P0967.
26. Harris HM, DelAguila M, Lopez JM et al. Anemia treatment costs in cancer patients treated with epoetin alfa or darbepoetin alfa in a managed care population. J Manag Care Pharm. 2005; 11:596. Abstract.
27. Varenterghem Y, Bàràny P, Mann JF et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int. 2002; 62:2167-75.
28. Locatelli F, Olivares J, Walker R et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int. 2001; 60:741-7.
29. Mark TL, McKenzie RS, Fastenau J et al. Retrospective observational study of patients with chemotherapy-related anemia receiving erythropoietic agents. Curr Med Res Opin. 2005; 21:1347-54.
30. Lefebvre P, Gosselin A, McKenzie RS et al. Dosing patterns, treatment costs, and frequency of physician visits in adults with cancer receiving erythropoietic agents in managed care organizations. Curr Med Res Opin. 2006; 22:1623-31.
31. Duh MS, Mody SH, McKenzie RS et al. Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations. Clin Ther. 2006; 28:1443-50.
32. Lyman GH, Berndt ER, Kallich JD et al. The economic burden of anemia in cancer patients receiving chemotherapy. Value Health. 2005; 8:149-56.